We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Changes Linked to Leukemia in Down’s Syndrome Children

By LabMedica International staff writers
Posted on 24 Jul 2019
Of the 30% of children with Down's syndrome who are found to have 'myeloid preleukemia', only 10% of those will go on to develop myeloid leukemia (3% of all children with Down's syndrome). More...
Until now, it was not understood why only some children with the GATA1 mutation were progressing to full leukemia, while others were not.

The specific gene mutations required for the development of leukemia in children with Down's syndrome have been discovered. Children with Down's syndrome have a 150-fold increased risk of myeloid leukemia, and while some of the genetic causes of this have been previously established, and a new study has identified a wide range of mutations and how they functionally interact to lead to leukemia.

An international team of scientists collaborating with those at the University of Oxford (Oxford, UK) combined exome and targeted resequencing of 111 transient abnormal myelopoiesis (TAM) and 141 myeloid leukemia-Downs’s syndrome (ML-DS) samples with functional analyses. TAM requires trisomy 21 and truncating mutations in GATA1; additional TAM variants are usually not pathogenic. By contrast, in ML-DS, clonal and subclonal variants are functionally required.

The scientists identified a recurrent and oncogenic hotspot gain-of-function mutation in myeloid cytokine receptor CSF2RB. By a multiplex CRISPR/Cas9 screen in an in vivo murine TAM model, they tested loss-of-function of 22 recurrently mutated ML-DS genes. Loss of 18 different genes produced leukemias that phenotypically, genetically, and transcriptionally mirrored ML-DS.

Paresh Vyas, MRCP FRCP FRCPath, a Professor of Hematology and a study author, said, “90% of babies with Down's syndrome do not go on to develop preleukemia. But until now, we did not fully understand why some babies did develop leukemia. 'To answer this question, we carefully characterized the mutations in genes required for leukemia to develop. We found that additional genetic changes are required in the altered GATA1 blood cells, and these additional changes transform the preleukemic blood cells into leukemic blood cells.” In total, 43 different altered genes were found. The study was published on July 11, 2019, in the journal Cancer Cell.

Related Links:
University of Oxford


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.